Pinned
Now available! AACE Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update #AACE2026
AACE
10.5K posts
AACE
@TheAACE
Official Twitter account for the American Association of Clinical Endocrinology (AACE). Elevating endocrinology since 1991.
Retweets ≠ endorsements.
- Just released! Our 2022 clinical practice guideline update for the care and management of people with or at risk for #diabetes. 170 new & updated recommendations included. Access the full guideline here: : pro.aace.com/disease-state-… #endotwitter
- Updated Type 2 Diabetes Algorithm! Our algorithm provides concise visual guidance with newer therapies & management approaches that build on previous versions, to assist you in your management of your patients with type 2 #diabetes. View it now: pro.aace.com/clinical-guida… #AACE2023
- Congratulations to the 2024 AACE Award recipients! Together, #WeAreAACE. Read more about each winner: pro.aace.com/about/awards/2… #endotwitter
- Just released! #NAFLD & #NASH guideline and treatment algorithm by AACE Co-Chairs Dr. Cusi & @scottisaacsmd. Access the full guideline here: pro.aace.com/disease-state-… #AACE2022 #endotwitter
- Just released at #AACECVMET - 2020 Algorithm on the Management of Dyslipidemia and Prevention of Cardiovascular Disease. Get it here: bit.ly/36tB1yR
- Phase 3 confirmatory trial data presented at #AACE2019 showed that Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease. Read more: bit.ly/2MYXUlR
- Introducing.... AACE Podcasts! In these 30 minute or less episodes, we cover topics and discussions in clinical endocrinology. 7 episodes are here now, with more to come. Listen now: bit.ly/3qfaHzb
- Welcome to a new AACE. Together, we are elevating clinical endocrinology to improve global health. Join us! Read today's announcement about our transformed brand and community here: bit.ly/2He2N8r #WeAreAACE
00:00 - Romosozumab significantly reduced vertebral, clinical, and nonvertebral fracture risk and increased BMD in women at very high fracture risk. Read the full article in the latest issue of #EndocrinePractice: endocrinepractice.org/article/S1530-… #endotwitter @Els_ENDO @vtangpricha
- Point/Counterpoint: SGLT-2 Inhibitor Use. This article describes the risks associated with the use of SGLT2i for the management of inpatient hyperglycemia: endocrinepractice.org/article/S1530-… #endotwitter @Els_ENDO @vtangpricha
- Point/Counterpoint: SGLT-2 Inhibitor Use. This article describes the risks associated with the use of SGLT2i for the management of inpatient hyperglycemia: endocrinepractice.org/article/S1530-… #endotwitter @Els_ENDO @vtangpricha
